AI
APRE icon

Atom Investors’s Aprea Therapeutics APRE Stock Holding History

Atom Investors’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,753
Closed -$843K – 373
2020
Q3 		$843K Buy
1,753
+1,469
+517% +$822K 0.08% 210
2020
Q2 		$221K Buy
+284
New +$186K 0.01% 348

Other funds holding APRE

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Atom Investors's APRE Position: Q4 2020 in Review

Atom Investors sold out of Aprea Therapeutics (APRE) in Q4 2020, closing a stake of 1,753 shares — an estimated $843K sold.

Atom Investors first reported a position in APRE in Q2 2020 and held it in 2 quarters. The position peaked at $843K in Q3 2020. 66 funds tracked by Wall St. Rank hold APRE as of Q4 2020.

  • Atom Investors reported no remaining Aprea Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Atom Investors sold 1,753 Aprea Therapeutics shares in Q4 2020, an estimated $843K.
  • Atom Investors first reported a position in Aprea Therapeutics in Q2 2020 and held it in 2 quarters.
  • Atom Investors's Aprea Therapeutics position peaked at $843K in Q3 2020.
  • 66 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q4 2020.

Based on Atom Investors's 13F filing for Q4 2020, filed 16 Feb 2021.